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Tuberculosis patients in the Dominican 
Republic face severe direct and indirect 
costs and need social protection
Verena Mauch,1 Ricardo Melgen,2 Belkys Marcelino,3  
Ivelisse Acosta,4 Eveline Klinkenberg,5 and Pedro Suarez6
Objective. To examine direct and indirect costs incurred by new, retreatment, and 
multidrug-resistant (MDR) tuberculosis (TB) patients in the Dominican Republic before 
and during diagnosis, and during treatment, to generate an evidence base and formulate 
recommendations.
Methods. The “Tool to Estimate Patients’ Costs” was adapted to the local setting, translated 
into Spanish, and pretested. Patients attending 32 randomly selected health facilities in six 
chosen study areas on the study days were interviewed. Responses from patients 18–65 years 
old who had received treatment for at least one month and provided signed informed consent 
were collected, entered into a database, and analyzed.
Results. A total of 200 patients were interviewed. For most respondents, direct and indirect 
costs increased while income decreased. Total costs amounted to a median of US$ 908 for 
new patients, US$ 432 for retreatment patients, and US$ 3 557 for MDR-TB patients. The 
proportion of patients without a regular income increased from 1% to 54% because of falling 
ill with TB. Following its review of the study results the Ministry of Health has made efforts 
to allocate public funds for food supplements and to include in- and outpatient TB services in 
the national health insurance schemes.
Conclusions. Free TB diagnosis and treatment are not enough to alleviate the financial 
constraints experienced by vulnerable groups as a result of the illness. Health insurance 
covering TB in- and outpatient costs is critical to prevent TB-related financial hardship.
Tuberculosis; tuberculosis, multidrug-resistant; cost of illness; Dominican Republic.
abstract
Key words
Tuberculosis (TB) is a major infec-
tious disease associated with poor liv-
ing standards and the socioeconomically 
disadvantaged (1, 2). In 2010, 214 030 
TB cases were notified in Latin America 
(total population 933 million), of which 
3 964 (1.85%) were in the Dominican 
Republic (equal to 1.07% of the country’s 
total population of 10 million) (3).7 In 
2007, the Pan American Health Orga-
nization (PAHO) (4) reported a rise in 
out-of-pocket expenses in the Dominican 
Republic mainly due to low government 
expenditures on health and a lack of fi-
nancial security in the form of insurance. 
While a number of studies on patient 
costs have been conducted in Africa (5–
9), until 2009 little evidence from Latin 
America was available in the literature 
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and none of the studies included costs 
incurred by multidrug-resistant tuber-
culosis (MDR-TB) patients. Studies done 
in Peru,8 Haiti (10), Mexico (11), and the 
Dominican Republic9 investigated the 
economic impact of TB. The study con-
ducted in the Dominican Republic found 
that the DOTS expansion strategy10 com-
bined with a patient-centered approach 
had a positive impact on TB control.
In 2009, the Dominican Republic Min-
istry of Health and its partners con-
ducted a study to determine the costs 
that TB patients incur. Direct (“out-of-
pocket”) and indirect (opportunity) costs 
of new, retreatment, and MDR-TB pa-
tients before and during diagnosis and 
during treatment were investigated. This 
was linked to information on patients’ 
socioeconomic status, health-seeking be-
havior, and HIV status, as well as the 
impact of TB on the welfare of the house-
hold. The study aimed to establish an 
evidence base upon which recommenda-
tions and interventions could be formu-
lated to address identified constraints. 
For this purpose, the research team de-
cided to use the “Tool to Estimate Pa-
tients’ Costs,” which has been validated 
and described elsewhere in detail (8) and 
can be downloaded for free.11 This article 
presents the findings of the study and 
the resulting actions.
In the Dominican Republic, diagnosis 
(sputum smear microscopy) and treat-
ment for TB is free of charge (including 
MDR-TB12) and is performed according 
to the DOTS expansion strategy (12). 
Fees are charged for x-rays. Upon di-
agnosis, new TB patients follow a six-
month treatment regimen (two months 
of four drugs daily followed by four 
months of two drugs taken three times 
weekly). Retreatment patients follow 
an eight-month regimen (five drugs 
for two months daily followed by one 
month of four drugs daily, followed by 
five months of two drugs taken three 
times weekly), and MDR-TB patients 
follow a 24-month treatment regimen 
(six months of five drugs daily followed 
by 18 months of two drugs daily). All 
TB patients are required to take their 
drugs under observation at health fa-
cilities throughout the entire course of 
treatment. 
MATERIALS AND METHODS 
Study sites
This study was descriptive and cross-
sectional. Three provincial health di-
rectorates (Santiago, La Vega, and San 
Cristóbal) and three health area director-
ates (Areas IV, V, and VIII) comprising 
both urban and rural areas were pur-
posively selected. Santiago and Areas 
IV, V, and VIII were chosen because of 
high TB caseloads (20.7% of the annual 
national case notification). San Cristóbal 
and La Vega were included because 
they have MDR-TB reference centers. 
Patients attending 32 randomly selected 
health facilities (public and private) in 
the six chosen study areas were sampled 
(Table 1). As this was an exploratory 
study, a target enrollment of 200 pa-
tients was considered a sample size suf-
ficiently powerful for statistical analysis.
Study population
Interviews were conducted during 
TB clinic days. The inclusion criteria 
included being a new, retreatment, or 
MDR-TB patient, having received treat-
ment for at least one month, and be-
ing between 18 and 65 years of age. 
MDR-TB patients included those who 
had initiated treatment for at least one 
month and no longer than three months 
at MDR-TB treatment sites and were 
previously treated with a standard re-
treatment regimen. Every TB patient that 
attended the selected health facility and 
fulfilled the above-mentioned inclusion 
criteria was asked to participate in the 
study. TB patients who had initiated but 
stopped treatment (“defaulters”), had 
a modified regimen due to treatment 
failure or adverse reactions, or declined 
to be interviewed were excluded from 
the study. All patients who agreed to be 
interviewed signed an informed consent 
form after being briefed on their rights. 
Questionnaire development and 
interviewer training
The questionnaire (8) was translated 
into Spanish, adapted to fit the local con-
text, and pretested in six health facilities 
representing all study areas. Based on the 
results of the pretest, the questionnaire 
was further adapted and back-translated 
into English to ensure accuracy of trans-
lation. Four interviewers were trained in 
a two-day course. Special attention was 
given to confidentiality, informed con-
sent, TB infection prevention, economic 
concepts, and costs. Interviews were 
conducted in Spanish. The study pro-
tocol and questionnaire were approved 
by the Independent Ethics Review Com-
mittee of the Asociación Dominicana 
Pro-Bienestar de la Familia (Profamilia), 
a nongovernmental organization (NGO) 
in the Dominican Republic. 
Data entry and analysis
Completed questionnaires were de-
livered to the field coordinator and re-
viewed for completeness. Thereafter 
questionnaires were coded and data was 
entered using Epi Info 3.4 (Centers for 
Disease Control and Prevention, Atlanta, 
Georgia, USA). Data was double-entered 
for consistency checks and analyzed 
using Microsoft Excel (Microsoft, Red-
mond, Washington, USA) and SPSS 13.0 
(SPSS Inc, Chicago, Illinois, USA). Me-
dian values were used for quantitative 
comparison to avoid distortion of results 
by outliers. Costs were reported in DR 
pesos (RD$) and converted to U.S. dol-
lars (US$) for analysis. At the time of the 
study (2009), the exchange rate was RD$ 
36.06 to US$1. Costs were distinguished 
as direct and indirect costs. Direct costs 
are out-of-pocket costs such as adminis-
trative fees, charges for tests and medi-
cines, transport, food, and accommoda-
tion. Transport and other costs related 
to health facility visits were calculated 
based on the number of trips required 
for a full course of treatment. Indirect 
costs included income, productivity, and 
time lost due to TB. To calculate income 
lost before the onset of the TB illness, lost 
working time was multiplied with the 
median reported individual income be-
fore the onset of TB. Pretreatment costs 
of MDR-TB patients were calculated in 
the same way as for new TB patients. 
Income lost during treatment was calcu-
lated by multiplying the time off work 
8  Ministerio de Salud (PE). Impacto económico de la 
tuberculosis en el Perú. Unpublished report 2001.
9  Acosta I, Marcelino B. Impact of DOTS expansion 
on TB-related outcomes and cost in the Dominican 
Republic. Unpublished report 2004.
10 As defined by the World Health Organization in the 
Stop TB Strategy (2006), the DOTS strategy includes 
five elements: 1) political commitment with in-
creased and sustained financing; 2) case detection 
through quality-assured bacteriology; 3) standard-
ized treatment with supervision and patient sup-
port (directly observed treatment, DOT); 4) an effec-
tive drug supply and management system; and 5) a 
monitoring and evaluation system, and impact 
measurement.
11 www.tbcare1.org/publications/toolbox/access/ 
and www.stoptb.org/wg/dots_expansion/tband-
poverty/spotlight.asp
12 Diagnosis: culture and drug-susceptibility testing 
are free; any other tests are charged. Treatment: all 
subscribed medications are free.
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with the median reported individual 
income since the onset of TB. Health in-
surance reimbursements were deducted. 
Interviewees were assigned to income 
groups according to the 2008 United Na-
tions Development Programme (UNDP) 
Human Development Report for the Do-
minican Republic (14). 
RESULTS 
A total of 200 individuals were inter-
viewed between 1 July and 30 August 
2009. Of those, 98% were patients and 
2% were people accompanying the pa-
tients (“guardians”). Two interviewees 
were excluded from the analysis due to 
incomplete data. No patient or guardian 
refused or stopped the interview. The 
majority of interviews (58%) took place 
in a hospital setting (85% of which were 
municipal hospitals) (Table 2). Table 3 
presents TB-related and socioeconomic 
information for the study sample popu-
lation. A total of 54.5% of the study 
population was male. The majority of 
respondents were 25–44 years old, 80% 
had primary education, and 5% were 
illiterate.
Health-seeking behavior
Almost 90% of respondents sought 
initial care in the private or public health 
care sector, with an almost equal number 
attending each different type (23% went 
to private facilities, 23% went to public 
clinics, and 23% and 21% went to munic-
ipal and regional hospitals respectively). 
Only 1.5% went to a traditional healer 
and less than 1% visited a pharmacy, but 
9% used homemade remedies as their 
initial care. The main reasons reported 
by the respondents for not visiting a 
public health facility when first seek-
ing care were lack of trust in the public 
health service (27%), distance (16%), and 
availability of private health insurance 
(23%). The median delay between on-
set of symptoms and seeking diagnosis 
was 6 weeks for men and 4.7 weeks for 
women. 
Pre-diagnosis and diagnosis costs
Direct. Most costs before and during di-
agnosis for new patients were attributed 
to medications not related to TB (36%), 
followed by costs for diagnostic tests not 
related to TB (21%), x-rays (18%), and ad-
ministrative costs (18%) (Table 4). X-rays 
are a costly component among diagnostic 
tests (9% of direct costs for retreatment pa-
tients and 5% for MDR-TB patients). Admin-
istrative costs included consultation costs 
and patient registration. Transportation, 
food, and accommodation costs constituted 
a comparatively small burden (7% all to-
gether). New patients spent a median of US$ 
47 on direct costs. Retreatment and MDR-TB 
patients spent more out-of-pocket money: 
on diagnostic tests related to TB (retreat-
TABLE 1. Socio-demographic, health, and tuberculosis (TB) data, Dominican Republic, 2009
Characteristic Dominican Republic Santiago La Vega San Cristóbal
Area IV  
(Santo Domingo)
Area V
(Distrito Nacional)
Area VIII  
(Santo Domingo)
Estimated population 9 755 954a 1 031 447b 647 003b 647 003b 500 846b 362 019b 254 931b
Estimated annual per capita 
income (US$)c 4 670a 1 679 1 580 2 035 –d 1 897 –
Number of TB cases notifiedb 4 256e 193 63 141 280 84 47
CNRf per 100 000 population 42 21 16 25 58 23 120
Estimated HIV prevalence 15–49 
years (%)g 0.9 0.7–0.9 0.7–0.9 0.5–0.6 0.5–0.6 0.5–0.6 0.5–0.6
Number of TB patients tested for 
HIVb 397 31 13 20 33 15 18
% HIV positive 9 8 14 7 7 8 9
Number of public health facilities 
per 100 000 populationh 28 13 22 20 – – –
Number of TB treatment centersb 1 068 70 55 75 40 30 18
Number of TB treatment centers 
per 100 000 population 10.9 6.8 8.5 11.6 7.9 8.3 7.1
a Reference 13.
b National Tuberculosis Control Program (DR). Annual Report. Unpublished report 2009. 
c Reference 14.
d
 Data not available.
e
 Reference 15. 
f
 CNR = case notification rate.
g
 Reference 16.
h
 Reference 17.
TABLE 2. Distribution of interview sites and patients surveyed by study area (three provinces 
and three health areas) for research on costs incurred by tuberculosis patients (n = 198), 
Dominican Republic, 2009
  Study area Number and type of interview sites Number of patients surveyed (%)
La Vega 1 hospital   4 (2)
Santiago 3 hospitals  40 (20)
San Cristóbal 3 hospitals  12 (6)
Area IV
(Santo Domingo)
1 community center
5 clinics
4 dispensaries
 55 (28)
Area V
(Distrito Nacional)
4 hospitals
4 clinics
3 dispensaries
 36 (18)
Area VIII
(Santo Domingo)
3 hospitals
1 clinic
 51 (26)
Total 32 198 (100)
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ment, 57% of all costs; MDR-TB, 72%) and 
medication unrelated to TB (retreatment, 
31% of all costs; MDR-TB, 7%). Altogether, 
retreatment patients spent a median of 
US$ 113 and MDR-TB patients US$ 154 on 
direct costs before and during diagnosis. 
Patients attending nonpublic sites incurred 
more median direct costs than those at-
tending public sector sites (US$ 53.6 versus 
US$ 8.3), mainly related to administrative 
charges, x-rays, and non-TB drugs.
Indirect. Indirect costs before and during 
diagnosis are mainly a result of the inability 
to work due to the illness. About 60% of 
respondents stopped working due to TB 
(Table 5). Of these, 48% stopped for more 
than six months. There were no significant 
differences among the respondents with 
respect to type of TB. 
Treatment costs (including 
hospitalization) 
Direct. Patients spent a median of US$ 151 
on direct costs during treatment. For those 
patients who had been hospitalized (33% of 
all respondents, 65 patients), costs associ-
ated with hospitalization accounted for 55% 
of all direct costs. On average, they were 
hospitalized for 25 days. Hospitalization 
costs, which included administrative and 
bedsheet fees, food, transport, medications, 
tests, and surgeries, were on average an 
additional US$ 61 for new patients, US$ 15 
for retreatment, and US$ 56 for MDR-TB pa-
tients. Women reported higher median costs 
while hospitalized than men (Figure 1). 
Nonhospitalized patients incurred 
direct costs during treatment mainly 
for food supplements and transport for 
treatment (DOTS), to collect TB medi-
TABLE 3. Characteristics of sample population 
for research on costs incurred by tuberculosis 
(TB) patients (n = 198), Dominican Republic, 
2009
Characteristic No. (%)a
Gender
Male  108 (54.5)
Female  90 (45.5)
Age (years)
18–24  40 (20)
25–44  106 (54)
≥ 45 52 (26)
Type of TB
Smear-positive 136 (69)
Smear-negative  22 (11)
Extra-pulmonary  40 (20)
Treatment category
New  150 (76)
Retreatment 28 (14)
MDR-TBb 20 (10)
Treatment site
Hospital  111 (56)
Clinics and dispensaries 85 (43)
Community  2 (1)
HIV status
Negative  130 (66)
Positive 22 (11)
No test  19 (10)
Results unknown 27 (14)
Education (interviewee)
Illiterate  10 (5)
Elementary school  159 (80)
Secondary school 1 (1)
University  27 (14)
Other  1 (1)
Type of work before TB
All year / regular 111 (56)
Seasonal / part-time  14 (7)
Day-to-day 32 (16)
Other  6 (3)
Does not work 35 (18)
Education (head of interviewee’s 
household)
Illiterate  8 (4)
Primary school  71 (36)
Secondary school 39 (20)
University 24 (12)
Other
Data not available
3 (1)
53 (27)
a Percentages may not sum to 100 because of rounding.
b
 MDR-TB: multidrug-resistant tuberculosis.
TABLE 4. Median direct costs incurred by tuberculosis (TB) patients (n = 198) by type of patient 
(new, retreatment, and MDR-TBa), Dominican Republic, 2009
Direct cost
Type of patient
New Retreatment
(in US$b)c
MDR-TB
Administrative fees (consultation costs and patient registration fees) 8.3 1.1 22.2
Diagnostic tests 10.4 63.8 110.9
X-rays 7.8 10.4 8.3
Medication 16.6 34.7 10.4
Transportation (round trip) 1.7 1.4 1.4
Meals 1.7 1.4 1.0
Lodging 0.0 0.0 0.0
Insurance reimbursement 0.0 0.0 0.0
Subtotal 46.5 112.7 154.1
Treatment
Monthly visits to health facility for DOTSd 23.3 28.6 58.2
Monthly visits to pick up medications 6.2 12.5 13.9
Monthly follow-up visits 16.6 16.6 49.9
Hospitalization 61.0 14.8 55.5
Food supplements (average monthly) 19.4 20.1 25.0
Insurance reimbursement 0.0 0.0 0.0
Subtotal 126.6 92.6 202.4
Total co-payments for TB-related health services paid by health 
insurance holders 8.3 5.5 55.5
Total 181.3 210.8 412.0
a
 MDR-TB: multidrug-resistant tuberculosis.
b
 US$1 = RD$ 36.06 (2009).
c Numbers may not sum to subtotals because of rounding.
d
 DOTS: directly observed treatment, short-course.
TABLE 5. Median indirect costs incurred by tuberculosis (TB) patients (n = 198) by type 
of patient (new, retreatment, MDR-TBa), Dominican Republic, 2009
Indirect cost
Type of patient
New Retreatment
(in US$b)
MDR-TB
Loss of income, productivity, and time due to:
Inability to work 660.0 180.3 2 785.4
DOTSc visits 6.1 3.7 9.7
Medication pickups 1.7 1.5 2.4
Follow-up visits 2.0 1.2 2.9
Hospitalization 56.6 34.2 345.5
Total 726.4 220.9 3 145.9
a
 MDR-TB: multidrug-resistant tuberculosis.
b
 US$1 = RD$ 36.06 (2009).
c
 DOTS: directly observed treatment, short-course.
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cines, and to conduct follow-up tests or 
pick up test results. Tables 4 and 5 pres-
ent direct and indirect costs incurred by 
new, retreatment, and MDR-TB patients. 
Indirect. Indirect costs during treatment 
were high due to inability to work, with a 
median of US$ 728. Only a small propor-
tion of indirect costs (1%) was associated 
with time spent on the road to and from 
health facilities, and waiting time. Median 
monthly indirect costs for treatment follow-
up (DOTS) were US$ 5, for medication 
collection US$ 1.50, and for follow-up tests 
US$ 2. On average, it took patients 73 min-
utes to travel to the health care center, pick 
up medications, and return home. Hospital-
ized patients incurred additional median in-
direct costs of US$ 69, probably due to long 
hospitalization, severe illness, and therefore 
longer inability to work. 
Coping costs
To compensate for the high costs they 
incurred after onset of TB, almost half of 
all respondents (45%) took up a loan and 
almost 20% sold property. Loans were 
mainly provided by family members 
or friends (80%). Among those paying 
interest on their loan, 37% paid an an-
nual percentage rate (APR) of more than 
10% (a direct cost). Of those respondents 
selling property, 43% sold household 
items, 14% sold vehicles, 8% land, and 
3% a house. When asked how TB ser-
vices could be improved to relieve the 
financial burden of respondents, 65% 
mentioned food coupons, 15% requested 
more efficient services, and 6% sug-
gested transport vouchers.
Guardian costs
About 12% of respondents reported 
having someone at their home (a guard-
ian) to assist them with care. Guardians 
are often family members who take time 
off work for this purpose and therefore 
incur indirect costs. According to the 
survey responses, about 75% of TB pa-
tients’ guardians stayed with them in 
their homes for more than two weeks. 
Guardians of new patients incurred a 
median cost of US$ 117 whereas guard-
ians of retreatment patients incurred 
US$ 73 and those of MDR-TB patients 
incurred US$ 176.
Total costs by treatment category and 
income group
MDR-TB patients incurred the highest 
overall costs. Indirect costs were higher 
than direct costs for all treatment cat-
egories (Table 6). Direct costs for new 
patients were highest during treatment, 
mainly related to hospitalization. For 
retreatment and MDR-TB patients, the 
largest portion of direct costs was attrib-
uted to diagnostic tests. 
The financial burden is particularly 
high on the lowest income group. Total 
costs for those who earn less than US$ 42 
per month represent 2 215% of median 
monthly income. MDR-TB patients are 
worst off because they incur the com-
paratively highest costs (8 676%). Except 
for retreatment patients, indirect costs 
mean a much higher financial burden 
than direct costs (approximately four 
times the direct costs for new patients 
and seven times for MDR-TB patients). 
Income groups changed remarkably due 
to TB (Figure 2). Before falling ill with 
TB, only about 1% of the study sample 
did not have a regular income. This 
proportion increased to 54% after the 
onset of TB (47% of new patients, 65% of 
retreatment patients, and 84% of MDR-
TB patients).
HIV and other comorbidities
Among the TB/HIV coinfected pa-
tients, 29% received antiretroviral treat-
ment (ART) and 20% had other comor-
bidities such as diabetes, high blood 
pressure, and arthritis. HIV-positive TB 
patients incurred higher costs than HIV-
negative patients. These higher costs 
were mainly related to additional visits 
to the health facility to collect ART medi-
cines and for follow-up treatment. Ad-
ditional health facility visits resulted in 
a median of US$ 7 more direct costs and 
US$ 603 more indirect costs for HIV-pos-
itive TB patients. However, HIV-positive 
patients incurred less total direct costs 
than HIV-negative patients because they 
were less often hospitalized and spent 
less on food and dietary supplements. 
Reduced spending on food and supple-
ments was mainly due to inability to 
spend more. When compared by type of 
treatment, more new patients were HIV 
positive (12%) than retreatment (11%) 
and MDR-TB patients (5%). However, as 
indicated in Table 3, not all respondents 
knew their HIV status (10% of new pa-
tients, 20% of retreatment patients, and 
25% of MDR-TB patients were unaware 
of their status). About 37% of HIV-
positive patients received services in the 
largest cities (Santiago and Santo Do-
mingo), and about 34% of respondents 
from these areas did not know their HIV 
status, which is higher than the reported 
average. 
55
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FIGURE 1. Median hospitalization costsa incurred by tuberculosis (TB) patients by gender and 
type of TB, Dominican Republic, 2009
a
 US$ 1 = RD$36.06 (2009).
b
 SSM+: smear-positive.
c
 SSM–: smear-negative.
d
 EPTB: Extra-pulmonary.
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Insurance
Approximately one-third of respon-
dents were covered by health insurance 
during the time of the study. Of these, 
62% obtained private insurance and 32% 
were part of the national health insur-
ance scheme. Two respondents received 
a median insurance reimbursement 
of US$ 1 000 for expenditures related 
to TB. The other 196 respondents did 
not receive any reimbursements. Most 
health insurance schemes in the DR 
do not cover TB-associated health care 
costs. 
DISCUSSION
Key findings
Findings of this study suggest that TB 
patients in the Dominican Republic face 
a severe financial burden as a result of 
falling ill with the disease. Information 
on the education level of the study popu-
lation (Table 3) suggests that this affects 
the most vulnerable of society. Due to 
TB, direct and indirect costs increased 
while income decreased for the majority 
of patients. The proportion of patients 
without a regular income increased from 
1% to 54% because of TB. Retreatment 
and MDR-TB patients are comparably 
worse off than new patients because of 
the severity of illness and related inabil-
ity to work, costly tests and medicines, 
and longevity of treatment. Patients at-
tending private clinics spent more than 
patients attending public sector sites. 
HIV-infected TB patients were disad-
vantaged by a lack of TB/HIV integrated 
services necessitating additional trips to 
health facilities. Guardians fulfill an im-
portant role in assisting patients during 
their appointments at the health facility 
and as treatment observers. The fact 
that almost half of all interviewed pa-
tients incurred debt and 65% of patients 
mentioned food coupons as a means to 
alleviate their situation underlines the 
severe impact TB has on the welfare of 
the household. This situation was exac-
erbated for those who were hospitalized 
and therefore incurred higher direct and 
indirect costs. The high costs of hospi-
talization and the length of stay could 
be related to delays in seeking care (5–6 
weeks) and therefore late diagnosis and 
advanced stage of the disease. Women 
incurred comparatively higher hospital-
ization costs than men, but it is not clear 
whether women were actually charged 
higher costs or estimated higher costs 
when interviewed. The information col-
lected on health-seeking behavior and 
HIV status, and the high proportion of 
direct costs for new patients for diagnos-
tic tests (22%) and medications (36%) un-
related to TB (particularly in private clin-
ics), suggests a lack of knowledge of HIV 
and TB among the general population.
Policy recommendations
Given the findings on the costs of 
hospitalization and HIV-related and di-
agnostic tests, in consultation with the 
Ministry of Health, the recommendation 
was made to improve the quality of care 
for TB patients in the private and pub-
lic primary care sectors. Furthermore, 
given the high hospitalization costs, de-
centralization of TB services at the pri-
mary care level was recommended to 
reduce the involvement of hospitals and 
shorten paths to diagnosis and treat-
ment. The lack of knowledge on TB and 
HIV prompted the recommendation to 
strengthen awareness-raising on TB and 
HIV among health care workers and 
the general population to reduce delays 
in diagnosis. The severe impact of TB-
related costs on the welfare of the house-
hold led to the recommendations to ad-
vocate for the inclusion of TB services in 
national health insurance schemes and 
to consider food and transport subsidies, 
especially for retreatment and MDR-TB 
patients. For better social and workplace 
reintegration of TB patients, collabora-
tion with other government institutions 
such as the Solidarity Program (Programa 
de Solidaridad); the “Eating Comes First” 
(“Comer Es Primero”) program; and the 
National Institute of Technical and Vo-
TABLE 6. Total median costs (direct and indirect) incurred by tuberculosis (TB) patients (n = 198) 
by type of patient (new, retreatment, and MDR-TBa), Dominican Republic, 2009
      Costs 
Type of patient
New Retreatment 
(in US$b)
MDR-TB 
Direct
 Before and during diagnosis
 Treatment 
 45.5 (26%)
134.9 (74%)
112.7 (54%)
 98.1 (46%)
  154.1 (37%)
  257.9 (63%)
Subtotal direct 180.4 (20%) 210.8 (49%)   412.0 (12%)
Indirect 726.4 (80%) 220.8 (51%) 3 145.0 (88%)
Total 906.8 431.6 3 557.0
a
 MDR-TB: multidrug-resistant tuberculosis.
b
 US$1 = RD$ 36.06 (2009).
FIGURE 2. Individual median monthly incomea among tuberculosis (TB) patients before and after 
onset of TB by income group, Dominican Republic, 2009b
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cational Training (Instituto de Formación 
Técnico Profesional, INFOTEP) was also 
recommended.
The Ministry of Health looked into the 
findings of this study in depth and ex-
plored the possibilities for implementing 
the recommendations. In 2011 it decided 
to move forward with allocating public 
funds for food supplements for TB pa-
tients and including in- and outpatient 
TB services in the national health insur-
ance schemes.
Study limitations
This study had some limitations. First, 
as areas with a high TB burden were 
purposively sampled, and TB is closely 
linked to poverty (1, 2), the purposive 
sampling method may have led to an 
over-representation of low-income pop-
ulations. Second, questions about costs 
and income are subject to recall bias and 
seasonal fluctuation (18). This is particu-
larly true for retreatment and MDR-TB 
patients, who often experience several 
health care–seeking episodes between 
onset of symptoms and diagnosis of 
drug-resistant TB. Including retreatment 
and MDR-TB patients in the study was 
nevertheless a deliberate choice of the 
study team, and was requested by the 
Ministry of Health, as these groups of 
patients have severe forms of the disease 
and require long-term treatment and are 
thus considered the most vulnerable. 
Third, estimating costs and incomes in 
monetary terms is difficult, particularly 
when distinguishing between income 
and turnover. Comparing the 2009 in-
come data with 2004 UNDP income data 
(14) reveals that half of the interviewees 
earned more per month (> US$ 166) 
before they became ill than the average 
population in 2004 (US$ 170.5; US$1 = 
RD$ 28.4). This could be attributed to 
overestimation in this study, or it could 
be due to increasing wages, economic 
growth, and inflation during that period. 
After onset of TB, however, the picture 
changes dramatically. The majority of 
TB patients earned less than US$ 42 per 
month, which is significantly less than 
the US$ 170.5 reported by the UNDP.
The contribution of external income 
sources from relatives or friends was not 
explicitly asked during interviews. Pre-
miums paid for health insurance were 
not deducted when calculating expendi-
tures. As only two patients received sig-
nificant reimbursements, however, this 
omission should not have had a large 
effect on results. Differences between 
the study areas were considered beyond 
the purpose of this study and thus were 
not determined by means of sensitivity 
testing.
Patient cost studies done in other parts 
of the world show similar findings (5–8, 
18–21). Although numbers cannot be 
directly compared due to the different 
methodologies employed, similar pat-
terns are visible: indirect costs are higher 
than direct costs and total costs are 
beyond 10% of annual income. These 
patterns indicate the need for the state to 
protect its population from the economic 
and health effects of contracting TB and 
to prevent an increase or deepening of 
poverty among those suffering from the 
disease. This finding also exemplifies 
the need to further investigate and limit 
costs incurred by MDR-TB patients. 
Conclusions
Findings of this study confirm a pattern 
shown by other TB patient cost studies 
in the world: TB patients in the DR 
face a great financial burden without 
the necessary social protection. Free TB 
diagnosis and treatment are not enough 
to alleviate the vulnerable from financial 
constraints due to the illness. Health 
insurance covering TB in- and outpatient 
costs and integrated TB/HIV services 
are crucial to prevent TB-related financial 
hardship. 
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